Zydus Cadila gets USFDA nod to sell BP lowering drug
Zydus Cadila gets USFDA nod to sell BP lowering drug
Cadila Healthcare today said its group firm Zydus Cadila has received the final approval from the US health regulator to market blood pressure medicine, Amlodipine and Olmesartan Medoxomil tablets.
The nod by US Food and Drug Administration (USFDA) is for multiple strengths of the tablets 5mg/40mg; 10mg/20mmg and 10mg/40 mg, the company said in a BSE filing.
"The drug is indicated for the treatment of hypertension, alone or with other anti-hypertensive agents to lower blood pressure and will be manufactured at the group's formulations manufacturing facility at Pharma SEZ Ahmedabad," Cadila Healthcare added.
The group has now more than 150 approvals and has so far filed over 300 abbreviated new drug applications (ANDAs) since the commencement of filing process in FY2003-04, it added.
(This article has not been edited by Zeebiz editorial team and is auto-generated from an agency feed.)
Get Latest Business News, Stock Market Updates and Videos; Check your tax outgo through Income Tax Calculator and save money through our Personal Finance coverage. Check Business Breaking News Live on Zee Business Twitter and Facebook. Subscribe on YouTube.